Prevalence of SARS-CoV-2 Antibodies in a Multistate Academic Medical Center
Copyright © 2021 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved..
OBJECTIVE: To estimate the seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in health care personnel.
METHODS: The Mayo Clinic Serology Screening Program was created to provide a voluntary, two-stage testing program for SARS-CoV-2 antibodies to health care personnel. The first stage used a dried blood spot screening test initiated on June 15, 2020. Those participants identified as reactive were advised to have confirmatory testing via a venipuncture. Venipuncture results through August 8, 2020, were considered. Consent and authorization for testing was required to participate in the screening program. This report, which was conducted under an institutional review board-approved protocol, only includes employees who have further authorized their records for use in research.
RESULTS: A total of 81,113 health care personnel were eligible for the program, and of these 29,606 participated in the screening program. A total of 4284 (14.5%) of the dried blood spot test results were "reactive" and warranted confirmatory testing. Confirmatory testing was completed on 4094 (95.6%) of the screen reactive with an overall seroprevalence rate of 0.60% (95% CI, 0.52% to 0.69%). Significant variation in seroprevalence was observed by region of the country and age group.
CONCLUSION: The seroprevalence for SARS-CoV-2 antibodies through August 8, 2020, was found to be lower than previously reported in other health care organizations. There was an observation that seroprevalence may be associated with community disease burden.
| Errataetall: |
CommentIn: Mayo Clin Proc. 2021 May;96(5):1101-1104. - PMID 33958044 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:96 |
|---|---|
| Enthalten in: |
Mayo Clinic proceedings - 96(2021), 5 vom: 15. Mai, Seite 1165-1174 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 18.05.2021 Date Revised 18.08.2021 published: Print-Electronic CommentIn: Mayo Clin Proc. 2021 May;96(5):1101-1104. - PMID 33958044 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.mayocp.2021.03.015 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM325099227 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM325099227 | ||
| 003 | DE-627 | ||
| 005 | 20231225191722.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.mayocp.2021.03.015 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1083.xml |
| 035 | |a (DE-627)NLM325099227 | ||
| 035 | |a (NLM)33958053 | ||
| 035 | |a (PII)S0025-6196(21)00232-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Carter, Rickey E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prevalence of SARS-CoV-2 Antibodies in a Multistate Academic Medical Center |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.05.2021 | ||
| 500 | |a Date Revised 18.08.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Mayo Clin Proc. 2021 May;96(5):1101-1104. - PMID 33958044 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a OBJECTIVE: To estimate the seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in health care personnel | ||
| 520 | |a METHODS: The Mayo Clinic Serology Screening Program was created to provide a voluntary, two-stage testing program for SARS-CoV-2 antibodies to health care personnel. The first stage used a dried blood spot screening test initiated on June 15, 2020. Those participants identified as reactive were advised to have confirmatory testing via a venipuncture. Venipuncture results through August 8, 2020, were considered. Consent and authorization for testing was required to participate in the screening program. This report, which was conducted under an institutional review board-approved protocol, only includes employees who have further authorized their records for use in research | ||
| 520 | |a RESULTS: A total of 81,113 health care personnel were eligible for the program, and of these 29,606 participated in the screening program. A total of 4284 (14.5%) of the dried blood spot test results were "reactive" and warranted confirmatory testing. Confirmatory testing was completed on 4094 (95.6%) of the screen reactive with an overall seroprevalence rate of 0.60% (95% CI, 0.52% to 0.69%). Significant variation in seroprevalence was observed by region of the country and age group | ||
| 520 | |a CONCLUSION: The seroprevalence for SARS-CoV-2 antibodies through August 8, 2020, was found to be lower than previously reported in other health care organizations. There was an observation that seroprevalence may be associated with community disease burden | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 700 | 1 | |a Theel, Elitza S |e verfasserin |4 aut | |
| 700 | 1 | |a Breeher, Laura E |e verfasserin |4 aut | |
| 700 | 1 | |a Swift, Melanie D |e verfasserin |4 aut | |
| 700 | 1 | |a Van Brunt, Nathan A |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Windell R |e verfasserin |4 aut | |
| 700 | 1 | |a Blanchfield, Lorrie L |e verfasserin |4 aut | |
| 700 | 1 | |a Daugherty, Elizabeth A |e verfasserin |4 aut | |
| 700 | 1 | |a Chapital, Alyssa B |e verfasserin |4 aut | |
| 700 | 1 | |a Matson, Kathleen M |e verfasserin |4 aut | |
| 700 | 1 | |a Bews, Katherine A |e verfasserin |4 aut | |
| 700 | 1 | |a Johnson, Patrick W |e verfasserin |4 aut | |
| 700 | 1 | |a Domnick, Robert A |e verfasserin |4 aut | |
| 700 | 1 | |a Joyce, Diane E |e verfasserin |4 aut | |
| 700 | 1 | |a Geyer, Holly L |e verfasserin |4 aut | |
| 700 | 1 | |a Granger, Dane |e verfasserin |4 aut | |
| 700 | 1 | |a Hilgart, Heather R |e verfasserin |4 aut | |
| 700 | 1 | |a Turgeon, Coleman T |e verfasserin |4 aut | |
| 700 | 1 | |a Sanders, Karen A |e verfasserin |4 aut | |
| 700 | 1 | |a Matern, Dietrich |e verfasserin |4 aut | |
| 700 | 1 | |a Nassar, Aziza |e verfasserin |4 aut | |
| 700 | 1 | |a Sampathkumar, Priya |e verfasserin |4 aut | |
| 700 | 1 | |a Hainy, Caitlin M |e verfasserin |4 aut | |
| 700 | 1 | |a Orford, Robert R |e verfasserin |4 aut | |
| 700 | 1 | |a Vachon, Celine M |e verfasserin |4 aut | |
| 700 | 1 | |a Didehban, Roshanak |e verfasserin |4 aut | |
| 700 | 1 | |a Morice, William G |e verfasserin |4 aut | |
| 700 | 1 | |a Ting, Henry H |e verfasserin |4 aut | |
| 700 | 1 | |a Williams, Amy W |e verfasserin |4 aut | |
| 700 | 1 | |a Gray, Richard J |e verfasserin |4 aut | |
| 700 | 1 | |a Thielen, Kent R |e verfasserin |4 aut | |
| 700 | 1 | |a Farrugia, Gianrico |e verfasserin |4 aut | |
| 700 | 0 | |a Mayo Clinic Serology Screening Program Operations Team |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Mayo Clinic proceedings |d 1964 |g 96(2021), 5 vom: 15. Mai, Seite 1165-1174 |w (DE-627)NLM000074527 |x 1942-5546 |7 nnns |
| 773 | 1 | 8 | |g volume:96 |g year:2021 |g number:5 |g day:15 |g month:05 |g pages:1165-1174 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.mayocp.2021.03.015 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 96 |j 2021 |e 5 |b 15 |c 05 |h 1165-1174 | ||